X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs LUPIN LTD - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD LUPIN LTD ORCHID PHARMA LTD/
LUPIN LTD
 
P/E (TTM) x 0.2 162.8 0.1% View Chart
P/BV x 0.2 3.0 6.7% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ORCHID PHARMA LTD   LUPIN LTD
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
LUPIN LTD
Mar-17
ORCHID PHARMA LTD/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1941,750 11.1%   
Low Rs351,384 2.5%   
Sales per share (Unadj.) Rs276.5387.4 71.4%  
Earnings per share (Unadj.) Rs-79.256.6 -139.9%  
Cash flow per share (Unadj.) Rs-43.576.8 -56.6%  
Dividends per share (Unadj.) Rs07.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs53.9298.9 18.0%  
Shares outstanding (eoy) m70.45451.58 15.6%   
Bonus/Rights/Conversions ESOPESOPS-  
Price / Sales ratio x0.44.0 10.2%   
Avg P/E ratio x-1.427.7 -5.2%  
P/CF ratio (eoy) x-2.620.4 -12.9%  
Price / Book Value ratio x2.15.2 40.5%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m8,067707,513 1.1%   
No. of employees `0002.816.8 16.7%   
Total wages/salary Rs m2,52728,495 8.9%   
Avg. sales/employee Rs Th6,956.110,418.3 66.8%   
Avg. wages/employee Rs Th902.51,697.0 53.2%   
Avg. net profit/employee Rs Th-1,993.01,523.0 -130.9%   
INCOME DATA
Net Sales Rs m19,477174,943 11.1%  
Other income Rs m4071,065 38.2%   
Total revenues Rs m19,884176,008 11.3%   
Gross profit Rs m1,10344,931 2.5%  
Depreciation Rs m2,5199,122 27.6%   
Interest Rs m5,2271,525 342.7%   
Profit before tax Rs m-6,23635,349 -17.6%   
Minority Interest Rs m20-72 -27.5%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1259,785 -1.3%   
Profit after tax Rs m-5,58025,575 -21.8%  
Gross profit margin %5.725.7 22.0%  
Effective tax rate %2.027.7 7.3%   
Net profit margin %-28.714.6 -196.0%  
BALANCE SHEET DATA
Current assets Rs m11,014119,542 9.2%   
Current liabilities Rs m32,06061,206 52.4%   
Net working cap to sales %-108.133.3 -324.0%  
Current ratio x0.32.0 17.6%  
Inventory Days Days9576 124.8%  
Debtors Days Days3490 37.3%  
Net fixed assets Rs m29,440131,660 22.4%   
Share capital Rs m705903 78.0%   
"Free" reserves Rs m2,043134,073 1.5%   
Net worth Rs m3,800134,976 2.8%   
Long term debt Rs m9,01856,478 16.0%   
Total assets Rs m46,510266,073 17.5%  
Interest coverage x-0.224.2 -0.8%   
Debt to equity ratio x2.40.4 567.2%  
Sales to assets ratio x0.40.7 63.7%   
Return on assets %-0.810.2 -7.5%  
Return on equity %-146.918.9 -775.1%  
Return on capital %-3.719.3 -19.4%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51381,885 9.2%   
Fx outflow Rs m5,64921,506 26.3%   
Net fx Rs m1,86560,378 3.1%   
CASH FLOW
From Operations Rs m1,68241,148 4.1%  
From Investments Rs m-9,860-25,287 39.0%  
From Financial Activity Rs m6,6444,332 153.4%  
Net Cashflow Rs m-1,53520,193 -7.6%  

Share Holding

Indian Promoters % 32.3 46.6 69.3%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 4.6 11.3 40.7%  
FIIs % 3.3 31.9 10.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 10.1 547.5%  
Shareholders   84,811 98,259 86.3%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   FDC LTD.  UNICHEM LAB  WYETH LTD  AJANTA PHARMA  ALEMBIC LTD  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jun 18, 2018 03:35 PM

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS